Harmony Biosciences Holdings Inc. Common Stock (HRMY)
Stock · NASDAQ · Health Care
$37.95as of 10/16/2026
Price chart
Active signals
HRMY Signal Track Record
How signals performed across all stocks →What HRMY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +0.7% | 55% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 28 | +1.6% | 57% | June 5, 2026 |
| Bollinger Band Breakdown | 22 | -0.7% | 50% | September 29, 2026 |
| Bollinger Band Breakout | 23 | -0.9% | 48% | September 1, 2026 |
| Any 20-session window (baseline) | +0.6% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinica…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 293
- Website
- www.harmonybiosciences.com/
Fundamentals
- 1-day range
- $36.58$38.17
- Market cap
- $2.26B
- P/E (trailing)
- 12.36
- P/E (forward)
- 5.23
- EPS (trailing)
- $3.09
- Dividend yield
- —
- Beta
- 0.98
- Avg. volume
- 897.2K
How Harmony Biosciences Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
Harmony Biosciences Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- HRMYHarmony Biosciences Holdings Inc. Common Stock$37.95▼ 0.84%Market cap $2.26BP/E 12.36$25.52$43.49
- SIONSionna Therapeutics Inc. Common Stock$3.89▼ 4.66%Market cap $2.24BP/E —$3.93$54.97
- PVLAPalvella Therapeutics Inc. Common Stock$120.3▼ 5.53%Market cap $2.23BP/E —$68.96$161.38
- MLYSMineralys Therapeutics Inc. Common Stock$20.3▼ 6.19%Market cap $2.23BP/E —$21.46$47.65
- URGNUroGen Pharma Ltd. Ordinary Shares$34.56▼ 5.60%Market cap $2.22BP/E —$16.37$50.81
- RAPPRapport Therapeutics Inc. Common Stock$27.57▼ 6.76%Market cap $2.22BP/E —$23.75$52.93
- VERAVera Therapeutics Inc. Class A Common Stock$27.88▼ 2.42%Market cap $2.30BP/E —$23.05$56.05
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| HRMY Harmony Biosciences Holdings Inc. Common Stock | $2.26B | 12.36 | $37.95 | ▼ 0.84% | $25.52$43.49 |
| SION Sionna Therapeutics Inc. Common Stock | $2.24B | — | $3.89 | ▼ 4.66% | $3.93$54.97 |
| PVLA Palvella Therapeutics Inc. Common Stock | $2.23B | — | $120.3 | ▼ 5.53% | $68.96$161.38 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $20.3 | ▼ 6.19% | $21.46$47.65 |
| URGN UroGen Pharma Ltd. Ordinary Shares | $2.22B | — | $34.56 | ▼ 5.60% | $16.37$50.81 |
| RAPP Rapport Therapeutics Inc. Common Stock | $2.22B | — | $27.57 | ▼ 6.76% | $23.75$52.93 |
| VERA Vera Therapeutics Inc. Class A Common Stock | $2.30B | — | $27.88 | ▼ 2.42% | $23.05$56.05 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Philip Ron M · May 14, 2026 · Grant21.9K
- Sabater Juan A. · May 14, 2026 · Grant21.9K
- Szyper Linda M · May 14, 2026 · Grant21.9K
- Gary Sender · May 14, 2026 · Grant21.9K
- R. Mark Graf · May 14, 2026 · Grant21.9K
- Germano Geno J · May 14, 2026 · Grant21.2K
- Budur Kumar · May 1, 2026 · Option Exercise18.8K
- Budur Kumar · May 1, 2026 · Tax Withholding8.9K @ $31.83
- Reicin Glenn · April 14, 2026 · Grant164.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 52.56M
- Total value held
- $1.32B
- Institutional holders
- 302
- Unknown7.07M
- Unknown3.16M
- Unknown2.11M
- Unknown2.10M
- Unknown2.08M
- Unknown2.03M
- Unknown2.02M
- Unknown1.78M
- Unknown1.62M
- Unknown1.38M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook
HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.
HRMY Reports New Phase 3 Data and Maintains Positive Analyst Outlook. HRMY shared new Phase 3 data at the European Narcolepsy Days, adding to its pipeline. Analysts remain upbeat, with Needham keeping a positive stance and a $50 target. The Wakix franchise also offers multiple value drivers. Shares rose 48% recently, yet the stock still trades below its 52‑week low.